钠-葡萄糖协同转运蛋白2抑制剂与二甲双胍对2型糖尿病合并代谢功能障碍相关脂肪性肝病患者肝脏及非肝脏并发症的协同关联
这项基于人群的队列研究从Merative Marketscan研究数据库(2013年4月至2021年12月)纳入2型糖尿病合并代谢功能障碍相关脂肪性肝病患者,比较SGLT-2i与其他降糖药对肝脏及非肝脏并发症的长期影响。结果显示SGLT-2i使用者肝细胞癌、肝硬化、心血管疾病、慢性肾脏病及非肝脏癌症风险均显著低于其他降糖药使用者,且联合二甲双胍风险进一步降低。
要点
- SGLT-2i与其他降糖药相比,肝细胞癌风险HR 0.76(95%CI 0.62-0.93),肝硬化风险HR 0.80(95%CI 0.76-0.84)。
- SGLT-2i使用者心血管疾病风险HR 0.82(95%CI 0.79-0.85),慢性肾脏病风险HR 0.66(95%CI 0.62-0.70)。
- 与未使用二甲双胍和SGLT-2i者相比,单用任一药物风险呈阶梯式下降(HR 0.76-0.97),联用两者风险进一步降低(HR 0.58-0.79)。
核心结论
- 在全国性队列中,合并糖尿病的代谢功能障碍相关脂肪性肝病患者使用SGLT-2i相比其他降糖药与肝脏及非肝脏并发症风险显著降低相关,联用二甲双胍时风险进一步降低。
研究设计与样本
- 基于人群的队列研究,从Merative Marketscan研究数据库(2013年4月至2021年12月)检索2型糖尿病合并代谢功能障碍相关脂肪性肝病患者,活性对照为其他降糖药,采用倾向性评分匹配和Cox回归模型。
主要发现
- 相比其他降糖药,SGLT-2i使用者肝细胞癌风险HR 0.76(95%CI 0.62-0.93),肝硬化风险HR 0.80(95%CI 0.76-0.84)。
- 相比其他降糖药,SGLT-2i使用者心血管疾病风险HR 0.82(95%CI 0.79-0.85),慢性肾脏病风险HR 0.66(95%CI 0.62-0.70),非肝脏癌症风险HR 0.81(95%CI 0.76-0.86)。
- 与未使用二甲双胍和SGLT-2i者相比,单用二甲双胍或SGLT-2i者风险呈阶梯式下降(HR 0.76-0.97),联用两者者风险进一步降低(HR 0.58-0.79)。
- 肝脏失代偿、代偿性肝硬化、主要心血管疾病、终末期肾病及特定常见癌症风险也较低(HR 0.61-0.84)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the long-term effect of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on liver and non-liver outcomes among patients with diabetic MASLD. DESIGN: This population-based cohort study retrieved patients with diabetic MASLD from Merative Marketscan Research Databases (April 2013 and December 2021). The active comparator was other glucose-lowering drugs (oGLDs). Primary outcomes were liver complications including hepatocellular carcinoma (HCC) and liver cirrhosis, as well as non-liver complications including cardiovascular disease (CVD), chronic kidney disease (CKD) and non-liver cancer. Propensity score matching was applied and Cox regression models were conducted. RESULTS: Compared with oGLD, SGLT-2i users had significantly lower risk of HCC (HR 0.76, 95% CI 0.62 to 0.93), liver cirrhosis (HR 0.80, 95% CI 0.76 to 0.84), CVD (HR 0.82, 95% CI 0.79 to 0.85) and CKD (HR 0.66, 95% CI 0.62 to 0.70), non-liver cancer (HR 0.81, 95% CI 0.76 to 0.86). Compared with patients without metformin and SGLT-2i, a stepwise decreasing risk was observed in users of either metformin or SGLT-2i (HRs 0.76-0.97) and in users of both medications (HRs 0.58-0.79). The lower risk also was shown in liver decompensation, compensated cirrhosis, major CVD, end-stage renal disease and specific common cancers (HRs 0.61-0.84). CONCLUSION: In a nationwide cohort, SGLT-2i users were associated with a substantially lower risk of liver and non-liver complications than oGLD users among patients with diabetic MASLD. The risk was further reduced with concomitant metformin use.
引用
- Mao X, Zhang X, Kam L, et al. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut. 2024. PMID: 39122360. doi:10.1136/gutjnl-2024-332481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。